Form 4: Iteos Therapeutics Director Acquires Stock Options

Director Robert Iannone acquired 24,200 stock options in Iteos Therapeutics, Inc. on June 11, 2024.

Summary

• On June 11, 2024, Robert Iannone, a director of Iteos Therapeutics, Inc., acquired 24,200 stock options.
• The exercise price of these options is $16.32.
• The options become exercisable on June 11, 2025, and expire on June 11, 2034.
• Following the transaction, Iannone directly owns 24,200 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally indicates confidence in the company's future, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biotechnology companies.
• The vesting schedule and expiration date of these options are within the standard range for such grants.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates